House Committee on Energy and Commerce

Drug Plan Fails, Signaling Thorny Path for Democrats’ $3.5 Trillion Bill

Senior Democrats said they could still preserve elements of their plan to lower prescription drug prices, but they have little room for defections, and divisions remain on that and other issues.

Drug Plan Fails, Signaling Thorny Path for Democrats’ $3.5 Trillion Bill

Senior Democrats said they could still preserve elements of their plan to lower prescription drug prices, but they have little room for defections, and divisions remain on that and other issues.

Drug Plan Fails, Signaling Thorny Path for Democrats’ $3.5 Trillion Bill

Senior Democrats said they could still preserve elements of their plan to lower prescription drug prices, but they have little room for defections, and divisions remain on that and other issues.

Democratic Divisions Flare Over Tax Increases and Drug Pricing

In both the House and the Senate, Democrats are working to resolve their internal differences on a huge social policy measure that will require near-total unity to pass.

Democratic Divisions Flare Over Tax Increases and Drug Pricing

In both the House and the Senate, Democrats are working to resolve their internal differences on a huge social policy measure that will require near-total unity to pass.

House Committees Demand F.D.A. Records on Alzheimer’s Drug Approval

The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.

House Committees Demand F.D.A. Records on Alzheimer’s Drug Approval

The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.

House Committees Demand F.D.A. Records on Alzheimer’s Drug Approval

The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.